A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

• Status: Recruiting
• Trial end date: 2031-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Collaborators: American Society of Clinical Oncology; Applebaum Foundation; Epizyme, Inc.

Criteria

Inclusion Criteria:

• Confirmed diagnosis of DLBCL, FL, or MCL

• Eligible to receive standard of care CAR T cells

• Have received at least 2 prior therapies

Exclusion Criteria:

• Active viral infection with HIV or hepatitis type B or C

• Active, uncontrolled systemic fungal, bacterial or viral infection

• Active treatment for another cancer

• Pregnant or breastfeeding